Immuron Travelan® Global sales up 216%
April 27 2022 - 6:00AM
Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian
biopharmaceutical company focused on developing and commercializing
oral immunotherapeutics for the treatment of gut mediated diseases,
today announced the sales results of its commercially available and
over-the-counter gastrointestinal and digestive health immune
supplement Travelan® for the third quarter of the fiscal year 2022,
ending on March 31, 2022.
North American Travelan® sales were up by 185%
and worldwide gross sales grew by 216% YoY in the third quarter of
FY22, reaching AU $193K compared to AU $61K in Q3 FY21. YTD March
31 FY22 worldwide Travelan® sales reached AU $392K marking a
healthy 340% increase on the same time last year.
In Australia, Travelan® sales increased to AU
$24K in Q3 FY22, representing an increase over Q3 FY21 (AU $2K).
Coming out of the pandemic and with international travel on the
increase we are starting to see positive signs of sales growth in
Q4.
In the US, Travelan® sales were AU $153K for Q3
FY22 (and AU $293K for YTD March 31 FY22) compared with nil for the
corresponding periods in FY21. This growth was attributable to
increasing sales in both Passport Health Travel Clinics and on the
Amazon e- commerce channel. While not at pre-pandemic peak, the
sales numbers in the US are starting to considerably pick up
again.
In mid to late March 2020, the COVID-19 pandemic
resulted in international travel restrictions being enacted in all
markets in which Travelan® is sold. This has had significant impact
on Travelan® sales over the last two years. Positive signs of
sales growth are starting to be demonstrated again, especially in
the US, for the first time since the pandemic began. It is
encouraging to see positive sales growth again which is correlating
well with the recommencement of international travel. We anticipate
sales will continue to improve in Q4 and during the next fiscal
year.
*Unaudited gross revenue
COMPANY CONTACT:Jerry
Kanellos, Ph.D. Chief Executive Officer Ph: +61 (0)3 9824
5254info@immuron.com
About
Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an
Australian biopharmaceutical company focused on developing and
commercializing orally delivered targeted polyclonal antibodies for
the treatment of inflammatory mediated and infectious diseases.
Immuron has a novel and safe technology platform with one
commercial asset generating revenue. In Australia, Travelan® is a
listed medicine on the Australian Register of Therapeutic Goods
(AUST L 106709) and is indicated to reduce the risk of Travellers’
Diarrhea, reduce the risk of minor gastro-intestinal disorders and
is antimicrobial. In Canada, Travelan® is a licenced natural health
product (NPN 80046016) and is indicated to reduce the risk of
Travellers’ Diarrhea. In the U.S., Travelan® is sold as a dietary
supplement for digestive tract protection in accordance with
section 403 (r)(6) of the Federal Drug Administration (FDA).
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jul 2023 to Jul 2024